Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S022 - Vitiligo

Saturday, February 17; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize a variety of presentations of vitiligo in both children and adults, and their implications for prognosis and treatment
  • Describe current therapies, their relative efficacy, and limitations
  • Discuss emerging treatments in the context of disease pathogenesis

Description

Recent discoveries in the pathogenesis, risk factors, and features of disease activity have influenced the way that we diagnose and manage vitiligo patients. Patterns of depigmentation in children and adults will be discussed, as well as their differential diagnoses and implications for prognosis and treatment. Current approaches to management and their comparative efficacy will be outlined, and emerging targeted therapies will be characterized. The goal is to empower attendees to approach vitiligo in a way that will lead to improved outcomes for their patients.

Disclosures

  • Desai, Seemal R., MD: AbbVie – C(Fees), I(Grants/Research Funding); Allergan, Inc – C(Fees); Cassiopea SpA – C(H); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(Fees); Galderma Laboratories, LP – C(Fees); Menlo Therapeutics – C(H), I(Grants/Research Funding); Or-Genix, Therapeutics – C(H); Ortho Dermatologics – C(H), SP(H); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); SkinCeuticals LLC – C(H); Symbio – I(Grants/Research Funding);
  • Ezzedine, Khaled, MD: no financial relationships exist with commercial interests.
  • Grimes, Pearl E., MD: Allergan, Inc. – C(H), I(Grants/Research Funding); Clinuvel – I(H); Derm Tech International – I(H); Galderma Laboratories, L.P. – C(Grants/Research Funding), C(H); Incyte Corporation – I(Grants/Research Funding); Kythera – I(H); Laseroptek USA – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Obagi Medical Products – I(H); Procter & Gamble Company – C(H); Suneva Medical, Inc. – I(H); VT Technologies – I(Grants/Research Funding);
  • Hamzavi, Iltefat H., MD: AbbVie – A(NC); Allergan, Inc. – I(Grants/Research Funding); Amgen – I(Fees); ChromaDerm – C(Fees); Clinuvel – I(Fees); Daavlin Company – I(EQ); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Pfizer Inc. – I(Fees);
  • Harris, John, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); BiologicsMD, Inc. – C(H); Celgene Corporation – I(Grants/Research Funding); Combe Incorporated – C(Fees); Concert Pharmaceuticals – A(H); EMD Serono – C(H); Genzyme Corporation – I(Grants/Research Funding); Janssen Biotech – C(H); Mitsibushi Pharma – C(H); Novartis – C(Fees); Pfizer Inc. – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); TeVido Biodevices, LLC – A(SO); Third Rock Ventures – A(H);
  • Houk, Laura, MD: no financial relationships exist with commercial interests.
  • Pandya, Amit G., MD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Clarify Medical Inc. – B(ST); Incyte Corporation – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding);
  • Passeron, Thierry: AbbVie – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Beiersdorf, Inc. – SP(H); Bioderma – Speaker/Faculty Education(H); Celgene Corporation – I(Grants/Research Funding); Galderma Research & Development, LLC – A(H); GlaxoSmithKline – Speaker/Faculty Education(H); ISDIN – SP(H); Janssen-Cilag – A(H); L'Oréal Research and Innovation – Speaker/Faculty Education(H); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H); Lancome – C(H); Lilly ICOS LLC – SP(H); MSD – A(H); Novartis – SP(H); Pfizer Inc. – A(H); Sanofi – A(H); Symrise – A(H); Syneron Candela – Speaker/Faculty Education(H);
  • Rodrigues, Michelle, MBBS: Cynosure, Inc. – A(NC); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(H);
Schedule
Saturday, February 17
9:00 AM
Dr. Harris / Introduction
9:15 AM
Ezzedine / Common, uncommon, and rare presentations of vitiligo
9:30 AM
Dr. Rodrigues / Vitiligo workup and differential diagnosis
9:45 AM
Dr. Desai / Chemicals that induce vitiligo: hazard and treatment
10:00 AM
Dr. Houk / Diet and supplements for vitiligo
10:15 AM
Dr. Harris, Ezzedine, Dr. Rodrigues, Dr. Desai, and Dr. Houk / Question and Answer
10:30 AM
Passeron / Medical therapy for vitiligo
10:45 AM
Dr. Pandya / Phototherapy for vitiligo
11:00 AM
Dr. Hamzavi / Surgical therapy for vitiligo
11:15 AM
Dr. Grimes / Special considerations in children with vitiligo
11:30 AM
Dr. Harris / Emerging vitiligo treatments
11:45 AM
Dr. Harris, Passeron, Dr. Pandya, Dr. Hamzavi, and Dr. Grimes / Question and Answer
Event Details
  • Date
    Saturday, February 17
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 28A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
Speakers